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THE EUROPEAN REGULATORY ISSUES
ON QUALITY OF LIFE ASSESSMENT
(ERIQA) PROJECT
Acquadro C
MAPI Research Institute, Lyon, France, for the ERIQA Group
BACKGROUND: The last 20 years have seen the develop-
ment of hundreds of health-related quality of life (HRQL)
instruments which are increasingly being used in multi-
national clinical trials. As a result, regulatory authorities
are more and more faced with HRQL as a new outcome
measure for the evaluation of new therapies. In 1997,
Mapi Research Institute organised an exploratory meet-
ing which brought together HRQL researchers and Euro-
pean regulatory representatives. The main objective was to
highlight the regulatory authorities’ concerns about HRQL
evaluation in clinical trials. Two conclusions were made:
1. There is a need to rationalise the field of HRQL re-
search and to make HRQL a credible criterion for the
evaluation of new therapies by health authorities; 2. This
issue can only be resolved through a better collaborative
effort between key players: health authorities, HRQL re-
searchers and pharmaceutical companies. Following these
conclusions, the ERIQA Project was launched.
OBJECTIVE: To provide European regulatory authorities
with guidance on how to assess the quality of HRQL stud-
ies in clinical trials, and how to evaluate the validity of
HRQL claims.
METHODS: The project is structured in 2 phases and 4
steps. Phase I will lead to the production of 3 types of doc-
uments, and presentations to regulatory authorities: 1. A
review of existing guidelines, focusing on EMEA docu-
ments; 2. A reference document, i.e., a guidance for the reg-
ulatory authorities to assess the quality of HRQL evalua-
tion and the validity of HRQL claims; 3. Pilot guidelines in
specific indications: cancer and COPD asthma. Phase II
will lead to consensus conferences with key players.
RESULTS: Preliminary results of Phase I will be pre-
sented. Collaboration with other similar US initiatives are
also planned.
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BACKGROUND: Within the last 20 years, a large num-
ber of HRQL instruments have been developed and are in-
creasingly being used in multinational research and clinical
practice. However, methodological issues relating to inter-
pretation of HRQL results still need to be clarified and
there is a need for improved interpretation of HRQL re-
sults. This could be achieved through the development of
reference values. Reference values provide a means of
comparing the results of an instrument’s administration
across populations and across disease severities. The use-
fulness of reference values to interpret the burden of
chronic disease has been illustrated in numerous studies.
OBJECTIVES: The purpose of this study was to review
the available medical literature to assess the current avail-
ability of HRQL reference values.
METHODS: A thorough search of the Medline and Index
Medicus database from 1966 to the present was con-
ducted that included the following search terms: “norma-
tive data”, norms, “reference levels”, “reference values”,
“quality of life”, and “health-related quality of life”.
RESULTS: A search of the Medline and Index Medicus da-
tabases yielded eight articles that referred to the develop-
ment of reference values and 61 articles describing compar-
ative studies where comparison were made of SF-36 scores
to those of established reference values. These articles in-
cluded the development and evaluation of reference values
of the Medical Outcomes Study Short Form Health Survey
SF-36 and the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire-C30.
CONCLUSIONS: Currently, few reference values exist,
particularly, for disease specific questionnaires. Clearly,
there is a critical need for the development of reference val-
ues for different diseases and populations according to
clinical and socio-demographic criteria. These reference
values may be used to make comparisons across popula-
tions and disease severities which will provide improved
interpretation of the results of HRQL studies.
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OBJECTIVE: Many clinical trials include an HRQL as-
sessment, but very few drugs have obtained labeling or
promotional approval. This is due in part to the poor qual-
ity of HRQL assessment and reporting. The objective of
the ERIQA group is to provide European regulatory au-
thorities with guidance on how to assess the quality of
